MA45843A - Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) - Google Patents

Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Info

Publication number
MA45843A
MA45843A MA045843A MA45843A MA45843A MA 45843 A MA45843 A MA 45843A MA 045843 A MA045843 A MA 045843A MA 45843 A MA45843 A MA 45843A MA 45843 A MA45843 A MA 45843A
Authority
MA
Morocco
Prior art keywords
ghrelin
goat
acyl transferase
transferase inhibitors
derivatives used
Prior art date
Application number
MA045843A
Other languages
English (en)
Other versions
MA45843B1 (fr
Inventor
Cédrickx Godbout
Thomas Trieselmann
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA45843A publication Critical patent/MA45843A/fr
Publication of MA45843B1 publication Critical patent/MA45843B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule générale (i) dans lesquels les groupes r1, r2 et n sont tels que définis dans la revendication 1, qui ont des propriétés pharmacologiques valorisables, en particulier, qui se lient au ghréline o-acyl transférase (chèvre) et modulent son activité. Ces composés conviennent pour traiter et prévenir des maladies pouvant être influencées par ce récepteur, telles que des maladies métaboliques, en particulier l'obésité
MA45843A 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) MA45843B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16183047 2016-08-05
PCT/EP2017/069274 WO2018024653A1 (fr) 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Publications (2)

Publication Number Publication Date
MA45843A true MA45843A (fr) 2019-06-12
MA45843B1 MA45843B1 (fr) 2021-06-30

Family

ID=56609762

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45843A MA45843B1 (fr) 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Country Status (32)

Country Link
US (3) US9994591B2 (fr)
EP (1) EP3494120B1 (fr)
JP (1) JP6651054B2 (fr)
KR (1) KR102496075B1 (fr)
CN (1) CN109843891B (fr)
AR (1) AR109296A1 (fr)
AU (1) AU2017307033B2 (fr)
CA (1) CA3033058A1 (fr)
CL (1) CL2019000274A1 (fr)
CO (1) CO2019000601A2 (fr)
CY (1) CY1124381T1 (fr)
DK (1) DK3494120T3 (fr)
EA (1) EA037277B1 (fr)
ES (1) ES2874587T3 (fr)
HR (1) HRP20210908T1 (fr)
HU (1) HUE054928T2 (fr)
IL (1) IL264506B (fr)
LT (1) LT3494120T (fr)
MA (1) MA45843B1 (fr)
MX (1) MX2019001427A (fr)
MY (1) MY197064A (fr)
PE (1) PE20190414A1 (fr)
PH (1) PH12019500254A1 (fr)
PL (1) PL3494120T3 (fr)
PT (1) PT3494120T (fr)
RS (1) RS61937B1 (fr)
SA (1) SA519401039B1 (fr)
SG (1) SG11201811804QA (fr)
SI (1) SI3494120T1 (fr)
TW (1) TWI749042B (fr)
UA (1) UA124267C2 (fr)
WO (1) WO2018024653A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630055B (zh) * 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
MA53075A (fr) 2018-02-02 2021-05-12 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
JP7150032B2 (ja) * 2018-02-02 2022-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
AU2019215710A1 (en) 2018-02-02 2020-07-23 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
EP4153600B1 (fr) 2020-05-22 2024-08-07 Boehringer Ingelheim International GmbH Procédé continu de fabrication de 7-amino-5-méthyl-[1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
PL4153599T3 (pl) 2020-05-22 2024-07-15 Boehringer Ingelheim International Gmbh Sposób wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4-b]pirydynokarboksylanu alkilu
CN112014340A (zh) * 2020-09-01 2020-12-01 广西玮美生物科技有限公司 非人灵长类动物胃饥饿素的检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
TW200831485A (en) 2006-12-11 2008-08-01 Boehringer Ingelheim Int New pyridazine derivatives with MCH antagonistic activity and medicaments comprising these compounds
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (fr) 2007-06-15 2008-12-18 Zealand Pharma A/S Analogues du glucagon
EP2370462B1 (fr) 2008-12-15 2014-07-16 Zealand Pharma A/S Analogues du glucagon
DK2370461T3 (da) 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
EA020520B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
WO2010070251A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
MX2014007120A (es) 2011-12-23 2015-03-05 Boehringer Ingelheim Int Analogos de glucagon.
JP6106179B2 (ja) * 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
EP3193939A4 (fr) * 2014-09-17 2018-10-24 The Regents of The University of California Petits inhibiteurs lipopeptidomimétiques de la ghréline o-acyl transférase
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MA53075A (fr) 2018-02-02 2021-05-12 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
JP7150032B2 (ja) 2018-02-02 2022-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
CN111630055B (zh) * 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
AU2019215710A1 (en) 2018-02-02 2020-07-23 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors

Also Published As

Publication number Publication date
AU2017307033A1 (en) 2019-01-17
PT3494120T (pt) 2021-05-26
US10308667B2 (en) 2019-06-04
EP3494120A1 (fr) 2019-06-12
ES2874587T3 (es) 2021-11-05
TWI749042B (zh) 2021-12-11
SG11201811804QA (en) 2019-01-30
IL264506A (en) 2019-02-28
EA037277B1 (ru) 2021-03-03
JP2019524786A (ja) 2019-09-05
SI3494120T1 (sl) 2021-08-31
CN109843891B (zh) 2021-11-23
PH12019500254A1 (en) 2019-06-03
AU2017307033B2 (en) 2020-11-26
CN109843891A (zh) 2019-06-04
KR102496075B1 (ko) 2023-02-06
MX2019001427A (es) 2019-06-10
US9994591B2 (en) 2018-06-12
EA201990418A1 (ru) 2019-08-30
MA45843B1 (fr) 2021-06-30
CY1124381T1 (el) 2022-07-22
PE20190414A1 (es) 2019-03-19
CO2019000601A2 (es) 2019-02-08
RS61937B1 (sr) 2021-07-30
NZ749290A (en) 2021-08-27
US20180037594A1 (en) 2018-02-08
WO2018024653A1 (fr) 2018-02-08
JP6651054B2 (ja) 2020-02-19
PL3494120T3 (pl) 2021-09-20
CA3033058A1 (fr) 2018-02-08
TW201817735A (zh) 2018-05-16
USRE49446E1 (en) 2023-03-07
CL2019000274A1 (es) 2019-05-03
US20180251476A1 (en) 2018-09-06
HRP20210908T1 (hr) 2021-09-03
SA519401039B1 (ar) 2021-11-25
LT3494120T (lt) 2021-05-25
AR109296A1 (es) 2018-11-14
UA124267C2 (uk) 2021-08-18
IL264506B (en) 2021-03-25
EP3494120B1 (fr) 2021-03-17
HUE054928T2 (hu) 2021-10-28
KR20190035859A (ko) 2019-04-03
DK3494120T3 (da) 2021-05-31
MY197064A (en) 2023-05-24

Similar Documents

Publication Publication Date Title
MA45843B1 (fr) Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
MA20150065A1 (fr) Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA38170A1 (fr) Nouveaux acides indanyloxydihydrobenzofuranylacétiques
EA200700617A1 (ru) Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
CR20200329A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MX2011003691A (es) Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
MA40993B1 (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
MA34839B1 (fr) Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes
MA31623B1 (fr) Nouveaux herbicides
CR20200331A (es) Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat)
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
EA201190004A1 (ru) Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3